- Home
- ADIL vs POAI Comparison
ADIL vs POAI Comparison
Compare ADIL & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADIL | POAI |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 6.5M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADIL | POAI |
|---|---|---|
| Price | $0.28 | $5.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 350.5K | 42.7K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,664,407.00 |
| Revenue This Year | N/A | $486.27 |
| Revenue Next Year | N/A | $65.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 320.71 |
| 52 Week Low | $0.22 | $3.88 |
| 52 Week High | $1.30 | $45.90 |
Technical Indicators
Market Signals| Indicator | ADIL | POAI |
|---|---|---|
| Relative Strength Index (RSI) | 32.77 | 47.30 |
| Support Level | $0.30 | $3.88 |
| Resistance Level | $0.32 | $6.25 |
| Average True Range (ATR) | 0.02 | 0.76 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 1.31 | 79.01 |
Price Performance
Historical ComparisonAbout ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.